Roche Unveils Promising Data for Giredestrant in Breast Cancer Therapy

Roche has announced significant findings regarding its oral selective estrogen receptor degrader (SERD), giredestrant, in the treatment of early-stage breast cancer. The results, presented at the **San Antonio Breast Cancer Symposium** (SABCS), indicate that giredestrant may enhance options for adjuvant therapy in patients diagnosed with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) early breast cancer.

The **lidERA trial** revealed a **30% reduction** in invasive disease-free survival (iDFS) with giredestrant when compared to standard endocrine therapy. Roche emphasized that giredestrant is the only oral SERD to achieve these results in a phase 3 trial within an adjuvant setting, marking a substantial advancement in endocrine therapy for this patient group in over **20 years**.

In addition to the iDFS results, there was a noted trend towards improved overall survival (OS) with giredestrant. At the three-year mark, **92.4%** of patients treated with the oral SERD were still alive, compared to **89.6%** in the endocrine therapy group. However, Roche acknowledged that this data remains immature and has not yet reached statistical significance.

Approximately **70%** of breast cancer cases are HR-positive, and it is concerning that up to a third of these patients may experience a recurrence during or after adjuvant endocrine therapy. The promising results from the lidERA trial may allow Roche to position giredestrant as a first-line option earlier in treatment compared to other drugs in the same class.

Currently, there are two oral SERDs on the market: **Menarini/Stemline’s Orserdu** (elacestrant) and **Eli Lilly’s Inluriyo** (imlunestrant). Both are approved as second-line treatments for advanced HR-positive/HER2-negative breast cancer with ESR1 mutations and are undergoing late-stage testing for adjuvant applications.

Notably, the lidERA trial commenced before the approvals of two CDK4/6 inhibitors, **Eli Lilly’s Verzenio** (abemaciclib) and **Novartis’ Kisqali** (ribociclib), which have also been shown to outperform endocrine therapy in their phase 3 trials. For instance, Verzenio, a blockbuster drug with annual sales exceeding **$5 billion**, has demonstrated a statistically significant **15.8%** improvement in OS when added to endocrine therapy, as reported in the monarchE trial.

In contrast, Kisqali, which reached **$3 billion** in sales last year thanks to its approval for both node-positive and node-negative patients, did not show a significant improvement in OS in the NATALEE trial. If giredestrant gains approval for adjuvant use, its market position will likely be influenced by various factors, including side effect profiles and the risk of recurrence among patients, as discussed during the SABCS presentations.

The evolving landscape of breast cancer treatment underscores the importance of continuous research and development, with Roche’s giredestrant representing a potential new option for patients facing the challenges of early-stage HR-positive breast cancer. As the data matures, it may provide critical insights into the future of adjuvant therapy in this domain.